NeuMoDx adds HPV test with pathology spin-off Self-screen

LabPulse.com staff writers
Oct 16, 2019
2019 05 17 20 09 8391 Hpv 400

NeuMoDx is working with the Netherlands-based biotech spin-off Self-screen on a CE-IVD Marked test for high-risk HPV that is compatible with its NeuMoDx 288 and 96 models.

Self-screen is a spin-off of Vrije Universiteit (VU) Amsterdam that specializes in cervical cancer screening and diagnostic testing. The company's CEO and co-founder is Dr. Chris Meijer, formerly the head of pathology and director of oncology research at VU Amsterdam. The company markets two polymerase chain reaction (PCR) products: the HPV-Risk assay for detecting high-risk genotypes and the QIAsure methylation test for ascertaining the risk of progression to cervical cancer.

Per the deal, Self-screen will obtain the CE Mark for its high-risk HPV genotype test on the NeuMoDx models, but NeuMoDx will manufacture and sell the product. NeuMoDx is partly owned by Qiagen, which is the exclusive distributor of NeuMoDx 288 and NeuMoDx 96 outside of the U.S.

Latest in HPV
Hpv Infection Social
HPV point-of-care test in development combines isothermal amplification, lateral flow detection
June 23, 2023
Lab Woman Dna Social
Roche receives WHO prequalification for HPV screening tool
June 13, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Head Neck Social
Mayo Clinic, Naveris collaborate to evaluate HPV DNA test in clinical trial
April 13, 2023
Related Stories
Hpv Infection Social
HPV
Mailed HPV home test kits doubled cervical cancer screening rates in study
2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400
COVID-19
NeuMoDx readies launch of automated SARS-CoV-2 assay
2020 02 05 22 27 6689 Head Neck 400
HPV
Naveris blood test spots recurrence of HPV cancers
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in HPV
HPV point-of-care test in development combines isothermal amplification, lateral flow detection
By LabPulse.com staff writers
A testing platform that combines the two technologies often used separately in diagnostic tests could simplify the equipment and procedures needed for HPV testing.
June 23, 2023
Hpv Infection Social
Roche receives WHO prequalification for HPV screening tool
By LabPulse.com staff writers
Prequalification helps expand access to the screening tool in countries that rely on the WHO's list of prequalified suppliers in making purchasing and implementation decisions.
June 13, 2023
Lab Woman Dna Social
Mailed HPV home test kits doubled cervical cancer screening rates in study
By Elissa Wolfson
Mailing human papillomavirus (HPV) self-collection kits for at-home use improved cervical cancer screening in under-screened, low-income women by nearly two-fold.
May 12, 2023
Hpv Infection Social
Mayo Clinic, Naveris collaborate to evaluate HPV DNA test in clinical trial
By LabPulse.com staff writers
The test is being developed with the aim of aiding treatment selection for patients with HPV-driven head and neck cancer.
April 13, 2023
Head Neck Social
Becton Dickinson HPV assay FDA approved with BD SurePath, Hologic ThinPrep Pap tests
By LabPulse.com staff writers
The BD Onclarity HPV Assay individually tests for an extended set of HPV types, including HPV 31, which poses a higher risk for causing cervical precancer than HPV 18, Becton Dickinson said.
February 21, 2023
Hpv Infection Social
BioReference offering Roche Diagnostics cytology test for women at high risk for HPV
By LabPulse.com staff writers
The test uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results.
February 9, 2023
Hpv Infection Social
Virax Biolabs obtains CE Mark, introduces human papillomavirus test kit
By LabPulse.com staff writers
The HPV test kit covers 18 genotypes of the human papillomavirus, including type 53, which is higher risk and becoming increasingly prevalent.
January 4, 2023
Hpv Infection Social
Enzo launches RNA gene expression platform for HPV
By LabPulse.com staff writers
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
2019 05 17 20 09 8391 Hpv 400
TTS, OmniPathology to offer oral HPV testing in L.A.
By LabPulse.com staff writers
A throat swab enables the detection of 14 high-risk strains of HPV by pathologists at OmniPathology's high-complexity, CLIA-certified pathology laboratory in Pasadena, CA.
August 16, 2022
2019 05 17 20 09 8391 Hpv 400
OmniPathology launches lab-developed test for HPV
By LabPulse.com staff writers
The PCR-based test detects 14 high-risk strains of HPV, a virus with potential to progress to cancer. It is performed on a throat swab submitted for testing to OmniPathology's CLIA-certified laboratory in Pasadena, CA, and helps screen for oropharyngeal cancer and early premalignant lesions.
July 11, 2022
2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400
Bio-Techne launches HPV assay in Europe
By LabPulse.com staff writers
RNAscope in situ hybridization (ISH) is a highly sensitive and specific spatial biology technology, Bio-Techne said.
July 5, 2022
2020 07 29 23 56 6775 Hpv Infection 400
Roche launches HPV self-sampling solution
By LabPulse.com staff writers
The patient self-collects a sample while at a healthcare facility, following instructions provided by a healthcare worker. Then the clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on one of its molecular instruments.
June 15, 2022
2020 07 29 23 56 6775 Hpv Infection 400
Page 1 of 3
Next Page